Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

CHINA-BEIJING-CIFTIS-VENUE (CN)

(220828) -- BEIJING, Aug. 28, 2022 (Xinhua) -- Photo taken on Aug. 28, 2022 shows the booth of the China National Biotec Group (CNBG) during a media preview of the 2022 China International Fair for Trade in Services (CIFTIS) at the China National Convention Center in Beijing, capital of China. The 2022 CIFTIS will be held at the China National Convention Center and the Shougang Park in Beijing from Aug. 31 to Sept. 5. (Xinhua/Cai Yang)

E

Myanmar starts administering locally produced Sinopharm COVID-19 vaccines

STORY: Myanmar starts administering locally produced Sinopharm COVID-19 vaccines DATELINE: May 5, 2022 LENGTH: 00:04:57 LOCATION: Yangon CATEGORY: HEALTH SHOTLIST: 1. various of the launching ceremony STORYLINE: Myanmar has begun administering locally filled-and-packed doses of China's Sinopharm COVID-19 vaccines, locally known as the Myancopharm vaccines, according to the Ministry of Health on Thursday. "The inoculation of Myancopharm COVID-19 vaccines has begun not only in Nay Pyi Taw and Yangon but also in other regions and states," Than Naing Soe, a director from the Ministry of Health, told Xinhua on Thursday. Union Minister for Health Thet Khaing Win observed the administering of Myancopharm COVID-19 vaccines in Nay Pyi Taw on Wednesday. Myanmar's Ministry of Industry, in collaboration with China National Biotec Group (CNBG), affiliated with Sinopharm, domestically packed and produced the Myancopharm COVID-19 vaccines. The health ministry said it received a total of 1 million doses o

E

CHINA-COVID-19-OMICRON-VACCINE-CLINICAL TRIAL (CN)

(220503) -- BEIJING, May 3, 2022 (Xinhua) -- Photo taken on April 22, 2022 shows the inactivated vaccine against Omicron variants developed by the China National Biotec Group affiliated with Sinopharm. The inactivated vaccine against Omicron variants developed by the China National Biotec Group affiliated with Sinopharm was approved for clinical trials by the National Medical Products Administration on April 26. The clinical trials are expected to conclude in three to four months and will be gradually put into use. (Xinhua)

E

CHINA-COVID-19-OMICRON-VACCINE-CLINICAL TRIAL (CN)

(220503) -- BEIJING, May 3, 2022 (Xinhua) -- A clinical trial volunteer receives a dose of China's inactivated vaccine against Omicron variants in Hangzhou, east China's Zhejiang Province, May 1, 2022. The inactivated vaccine against Omicron variants developed by the China National Biotec Group affiliated with Sinopharm was approved for clinical trials by the National Medical Products Administration on April 26. The clinical trials are expected to conclude in three to four months and will be gradually put into use. (Xinhua)

E

CHINA-COVID-19-OMICRON-VACCINE-CLINICAL TRIAL (CN)

(220503) -- BEIJING, May 3, 2022 (Xinhua) -- A clinical trial volunteer receives a dose of China's inactivated vaccine against Omicron variants in Hangzhou, east China's Zhejiang Province, May 2, 2022. The inactivated vaccine against Omicron variants developed by the China National Biotec Group affiliated with Sinopharm was approved for clinical trials by the National Medical Products Administration on April 26. The clinical trials are expected to conclude in three to four months and will be gradually put into use. (Xinhua)

E

CHINA-COVID-19-OMICRON-VACCINE-CLINICAL TRIAL (CN)

(220503) -- BEIJING, May 3, 2022 (Xinhua) -- A clinical trial volunteer receives a dose of China's inactivated vaccine against Omicron variants in Hangzhou, east China's Zhejiang Province, May 1, 2022. The inactivated vaccine against Omicron variants developed by the China National Biotec Group affiliated with Sinopharm was approved for clinical trials by the National Medical Products Administration on April 26. The clinical trials are expected to conclude in three to four months and will be gradually put into use. (Xinhua)